TY  - JOUR
AU  - Oeckl, Patrick
AU  - Abu-Rumeileh, Samir
AU  - Weise, Christopher M
AU  - Otto, Markus
TI  - Longitudinal changes of blood β-synuclein in cognitively unimpaired, mild cognitive impairment and sporadic Alzheimer´s disease.
JO  - Alzheimer's research & therapy
VL  - 18
IS  - 1
SN  - 1758-9193
CY  - London
PB  - BioMed Central
M1  - DZNE-2026-00237
SP  - 45
PY  - 2026
AB  - β-Synuclein is an emerging synaptic blood biomarker for Alzheimer´s disease (AD) and correlates with cognitive impairment, brain atrophy and amyloid/tau pathology. Longitudinal data from individual patients are missing so far but are important to evaluate how changes of β-synuclein might be used in early diagnosis, prediction, disease progression and treatment monitoring.In this observational study, we investigated serum β-synuclein by immunoprecipitation-mass spectrometry (IP-MS) in 463 participants from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) including clinically diagnosed cognitively unimpaired, mild cognitive impairment (MCI) and AD dementia subjects with ≥ 1 follow-up samples for 235 individuals and clinical follow-up for up to 19 years. CSF AD biomarker levels were available for 194 participants.Participants (40.0
KW  - Blood biomarker (Other)
KW  - Longitudinal observation (Other)
KW  - Mild cognitive impairment (Other)
KW  - Sporadic Alzheimer´s disease (Other)
KW  - Synaptic degeneration (Other)
KW  - β-synuclein (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:41673920
C2  - pmc:PMC12930813
DO  - DOI:10.1186/s13195-026-01973-1
UR  - https://pub.dzne.de/record/285455
ER  -